Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia

• Status: Completed
• Trial end date: 2006-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purposes of this study are to assess similarities and differences in the efficacy (how well the drug works), safety, and side effects of olanzapine and aripiprazole in patients with schizophrenia, schizoaffective disorder, or schizophreniform disorder.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Aripiprazole; Olanzapine

Criteria

Inclusion Criteria:

• Patients must have schizophrenia, schizoaffective disorder, or schizophreniform disorder

• Patients must be agitated

• Patients must display psychotic symptoms

• Patients must be inpatients who are expected to stay in the hospital for at least 5 days

• Patients must be 18 to 55 years of age

Exclusion Criteria:

• Patients may not be hospitalized for greater than 72 hours prior to study start

• Patients may not have received more than one dose of olanzapine or aripiprazole within 72 hours prior to study start

• Patients may not be actively suicidal

• Patients may not be diagnosed with substance-induced psychosis or substance dependence

• Patients may not have acute, serious, or unstable medical conditions